# Viloxazine - Newer non-stimulant (SNRI)
# Currently US-only

id: "viloxazine"

brandNames:
  US: ["Qelbree"]
  CN: []
  EU: []
  JP: []
  UK: []
  AU: []
  CA: []

genericName:
  en: "viloxazine hydrochloride"
  zh: "盐酸维洛沙嗪"
  ja: "ビロキサジン塩酸塩"

manufacturers:
  - name: "Supernus Pharmaceuticals"
    region: "US"
    product: "Qelbree"

# Classification
drugClass: "non-stimulant"

drugClassLabel:
  en: "Non-Stimulant"
  zh: "非兴奋剂"
  ja: "非中枢刺激薬"

category: "SNRI (selective norepinephrine reuptake inhibitor)"

categoryLabel:
  en: "Selective Norepinephrine Reuptake Inhibitor"
  zh: "选择性去甲肾上腺素再摄取抑制剂"
  ja: "選択的ノルエピネフリン再取り込み阻害薬"
controlledSubstance: false
schedule:
  US: "Not scheduled"
  CN: "Not approved"
  EU: "Not approved"
  JP: "Not approved"
  UK: "Not approved"

# Mechanism
activeIngredient:
  en: "viloxazine hydrochloride"
  zh: "盐酸维洛沙嗪"
  ja: "ビロキサジン塩酸塩"

mechanismOfAction:
  en: "Selective norepinephrine reuptake inhibitor with additional serotonergic activity (5-HT2B receptor antagonism and 5-HT2C receptor modulation). Increases norepinephrine levels in the prefrontal cortex to improve attention and executive function."
  zh: "选择性去甲肾上腺素再摄取抑制剂，具有额外的血清素能活性（5-HT2B受体拮抗和5-HT2C受体调节）。增加前额叶皮层去甲肾上腺素水平，改善注意力和执行功能。"
  ja: "選択的ノルエピネフリン再取り込み阻害薬で、セロトニン作動活性も有する（5-HT2B受容体拮抗および5-HT2C受容体調節）。前頭前皮質のノルエピネフリン濃度を上昇させ、注意力と実行機能を改善します。"
neurotransmittersAffected:
  - norepinephrine
  - serotonin

# Dosage & Forms
forms:
  - type: "capsule"
    typeLabel:
      en: "Capsule"
      zh: "胶囊"
      ja: "カプセル"
    releaseType: "extended"
    releaseTypeLabel:
      en: "Extended Release"
      zh: "缓释"
      ja: "徐放性"
    brandName: "Qelbree"
    strengths: ["100mg", "150mg", "200mg"]
    durationHours: 24
    notes:
      en: "Children 6-11: 100-400mg; can be opened and sprinkled on applesauce"
      zh: "6-11岁儿童：100-400mg；可打开撒在苹果酱上"
      ja: "6〜11歳の小児：100〜400mg；カプセルを開けてアップルソースにふりかけることができます"

  - type: "capsule"
    typeLabel:
      en: "Capsule"
      zh: "胶囊"
      ja: "カプセル"
    releaseType: "extended"
    releaseTypeLabel:
      en: "Extended Release"
      zh: "缓释"
      ja: "徐放性"
    brandName: "Qelbree"
    strengths: ["200mg", "400mg", "600mg"]
    durationHours: 24
    notes:
      en: "Adolescents 12-17 and adults: 200-600mg"
      zh: "12-17岁青少年和成人：200-600mg"
      ja: "12〜17歳の青年および成人：200〜600mg"

# Efficacy
onsetMinutes: null  # Gradual onset
peakEffectHours: 5
durationHours: 24

# Side Effects
sideEffects:
  common:
    - name:
        en: "somnolence/fatigue"
        zh: "嗜睡/疲劳"
        ja: "傾眠/疲労"
      frequency: "15-20%"
    - name:
        en: "decreased appetite"
        zh: "食欲下降"
        ja: "食欲減退"
      frequency: "10-15%"
    - name:
        en: "nausea"
        zh: "恶心"
        ja: "悪心"
      frequency: "10-15%"
    - name:
        en: "headache"
        zh: "头痛"
        ja: "頭痛"
      frequency: "10%"
    - name:
        en: "irritability"
        zh: "易怒"
        ja: "易刺激性"
      frequency: "5-10%"
    - name:
        en: "vomiting"
        zh: "呕吐"
        ja: "嘔吐"
      frequency: "5-10%"
    - name:
        en: "insomnia"
        zh: "失眠"
        ja: "不眠"
      frequency: "5%"

  uncommon:
    - name:
        en: "abdominal pain"
        zh: "腹痛"
        ja: "腹痛"
      frequency: "5%"
    - name:
        en: "tachycardia"
        zh: "心动过速"
        ja: "頻脈"
      frequency: "<5%"
    - name:
        en: "increased blood pressure"
        zh: "血压升高"
        ja: "血圧上昇"
      frequency: "<5%"
    - name:
        en: "weight loss"
        zh: "体重减轻"
        ja: "体重減少"
      frequency: "<5%"

  serious:
    - name:
        en: "suicidal ideation"
        zh: "自杀意念"
        ja: "自殺念慮"
      notes:
        en: "Black box warning; monitor closely, especially early in treatment"
        zh: "黑框警告；需密切监测，尤其是治疗初期"
        ja: "ブラックボックス警告；特に治療初期は注意深くモニタリングが必要"
    - name:
        en: "activation of mania/hypomania"
        zh: "诱发躁狂/轻躁狂"
        ja: "躁病/軽躁病の誘発"
      notes:
        en: "Can trigger in susceptible patients"
        zh: "易感患者可能诱发"
        ja: "感受性の高い患者で誘発される可能性"
    - name:
        en: "serotonin syndrome"
        zh: "血清素综合征"
        ja: "セロトニン症候群"
      notes:
        en: "When combined with serotonergic medications"
        zh: "与血清素能药物联用时"
        ja: "セロトニン作動薬との併用時"
    - name:
        en: "hypertensive crisis"
        zh: "高血压危象"
        ja: "高血圧クリーゼ"
      notes:
        en: "Avoid with MAOIs"
        zh: "避免与MAO抑制剂联用"
        ja: "MAOIとの併用を避ける"

# Safety
contraindications:
  en:
    - "Hypersensitivity to viloxazine"
    - "MAO inhibitor use within 14 days"
    - "Concomitant use of sensitive CYP1A2 substrates (e.g., tizanidine, alosetron)"
  zh:
    - "对维洛沙嗪过敏"
    - "14天内使用过MAO抑制剂"
    - "同时使用敏感的CYP1A2底物（如替扎尼定、阿洛司琼）"
  ja:
    - "ビロキサジンに対する過敏症"
    - "14日以内のMAO阻害剤使用"
    - "感受性の高いCYP1A2基質との併用（例：チザニジン、アロセトロン）"

drugInteractions:
  - drug:
      en: "MAO inhibitors"
      zh: "MAO抑制剂"
      ja: "MAO阻害剤"
    severity: "major"
    effect:
      en: "Risk of serotonin syndrome and hypertensive crisis"
      zh: "血清素综合征和高血压危象风险"
      ja: "セロトニン症候群および高血圧クリーゼのリスク"
  - drug:
      en: "CYP1A2 substrates (theophylline, duloxetine)"
      zh: "CYP1A2底物（茶碱、度洛西汀）"
      ja: "CYP1A2基質（テオフィリン、デュロキセチン）"
    severity: "major"
    effect:
      en: "Significantly increases levels of CYP1A2 substrates"
      zh: "显著增加CYP1A2底物血药浓度"
      ja: "CYP1A2基質の濃度を著しく上昇させる"
  - drug:
      en: "Serotonergic drugs"
      zh: "血清素能药物"
      ja: "セロトニン作動薬"
    severity: "moderate"
    effect:
      en: "Increased serotonin syndrome risk"
      zh: "血清素综合征风险增加"
      ja: "セロトニン症候群リスクの増加"
  - drug:
      en: "Seizure threshold-lowering drugs"
      zh: "降低癫痫阈值的药物"
      ja: "発作閾値を下げる薬物"
    severity: "moderate"
    effect:
      en: "May increase seizure risk"
      zh: "可能增加癫痫发作风险"
      ja: "発作リスクを増加させる可能性"

blackBoxWarnings:
  en:
    - "Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults"
  zh:
    - "儿童、青少年和年轻成人自杀想法和行为风险增加"
  ja:
    - "小児、青年、若年成人における自殺念慮および自殺行動のリスク増加"

pregnancyCategory: "C"

foodInteractions:
  en: "Can be taken with or without food"
  zh: "可随餐或空腹服用"
  ja: "食事の有無にかかわらず服用可能"

# Practical Information
typicalDosing:
  children:
    startingDose: "100mg once daily in morning"
    maxDose: "400mg/day (ages 6-11)"
    notes:
      en: "May increase by 100mg weekly"
      zh: "可每周增加100mg"
      ja: "毎週100mgずつ増量可能"
  adults:
    startingDose: "200mg once daily in morning"
    maxDose: "600mg/day"
    notes:
      en: "May increase by 200mg weekly"
      zh: "可每周增加200mg"
      ja: "毎週200mgずつ増量可能"

costEstimate:
  US:
    brand: "$350-450/month"
    generic: "Not yet available"
  CN:
    brand: "Not available"
    generic: "Not available"

storageRequirements:
  en: "Room temperature (20-25°C)"
  zh: "室温保存（20-25°C）"
  ja: "室温（20-25°C）で保存"

# Approval & Availability
approvals:
  - region: "US"
    agency: "FDA"
    year: 2021
    approvedAges:
      en: "6 years and older (children and adults)"
      zh: "6岁及以上（儿童和成人）"
      ja: "6歳以上（小児および成人）"
    indications:
      en: ["ADHD"]
      zh: ["注意缺陷多动障碍"]
      ja: ["ADHD"]
    available: true
    notes:
      en: "Children ages 6-11 approved April 2021; adults approved April 2022"
      zh: "6-11岁儿童于2021年4月获批；成人于2022年4月获批"
      ja: "6〜11歳の小児は2021年4月承認；成人は2022年4月承認"

  - region: "CN"
    agency: "NMPA"
    year: null
    approvedAges:
      en: ""
      zh: ""
      ja: ""
    indications:
      en: []
      zh: []
      ja: []
    available: false
    notes:
      en: "Not approved"
      zh: "未批准"
      ja: "未承認"

  - region: "EU"
    agency: "EMA"
    year: null
    approvedAges:
      en: ""
      zh: ""
      ja: ""
    indications:
      en: []
      zh: []
      ja: []
    available: false
    notes:
      en: "Not approved (was previously marketed for depression in EU in 1970s-1980s)"
      zh: "未批准（20世纪70-80年代曾在欧盟作为抗抑郁药销售）"
      ja: "未承認（1970〜1980年代にEUでうつ病薬として販売されていた）"

  - region: "JP"
    agency: "PMDA"
    year: null
    approvedAges:
      en: ""
      zh: ""
      ja: ""
    indications:
      en: []
      zh: []
      ja: []
    available: false
    notes:
      en: "Not approved"
      zh: "未批准"
      ja: "未承認"

  - region: "UK"
    agency: "MHRA"
    year: null
    approvedAges:
      en: ""
      zh: ""
      ja: ""
    indications:
      en: []
      zh: []
      ja: []
    available: false
    notes:
      en: "Not approved"
      zh: "未批准"
      ja: "未承認"

# Special Considerations
specialConsiderations:
  cardiacRisk:
    en: "Can increase heart rate and blood pressure; monitor"
    zh: "可增加心率和血压；需监测"
    ja: "心拍数と血圧を上昇させる可能性；モニタリングが必要"
  abuseRisk:
    en: "No abuse potential; not a controlled substance"
    zh: "无滥用风险；非管制药物"
    ja: "乱用の可能性なし；規制物質ではない"
  withdrawalNotes:
    en: "No significant withdrawal; can be stopped without tapering"
    zh: "无明显戒断症状；可直接停药无需减量"
    ja: "重大な離脱症状なし；漸減なしで中止可能"
  monitoringRequired:
    en: "Monitor for suicidality, especially early; blood pressure; heart rate"
    zh: "监测自杀倾向（尤其是初期）；血压；心率"
    ja: "自殺傾向のモニタリング（特に初期）；血圧；心拍数"

# Metadata
lastUpdated: 2025-12-02

sources:
  - "https://www.goodrx.com/conditions/adhd/non-stimulant-adhd-meds"
  - "https://www.additudemag.com/adhd-medications-list-chart-stimulants-nonstimulants/"
  - "https://medx.it.com/what-are-the-new-adhd-medications-in-2025-an-overview-of-treatments-and-innovations"

notes:
  en: "Newest non-stimulant option (2021). Structurally different from atomoxetine despite similar mechanism. Was previously used for depression in Europe (1970s-1980s) but withdrawn. Repurposed and FDA-approved for ADHD. Currently only available in US."
  zh: "最新的非兴奋剂选择（2021年）。尽管作用机制相似，但结构与托莫西汀不同。曾在20世纪70-80年代在欧洲用于抗抑郁但已撤市。重新定位并获FDA批准用于ADHD。目前仅在美国上市。"
  ja: "最新の非刺激薬オプション（2021年）。同様の作用機序にもかかわらず、アトモキセチンとは構造が異なる。1970〜1980年代にヨーロッパでうつ病に使用されていたが撤退。ADHDに再利用されFDA承認。現在は米国でのみ利用可能。"
